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Amiodarone is frequently used to treat arrhythmias in patients supported with left 
ventricular assist devices. Long term amiodarone use can cause hyperthyroidism 
ultimately leading to cardiomyopathy and sometimes thyrotoxicosis-induced 
cardiogenic shock (CS). We describe two cases of thyrotoxicosis-induced CS 
rescued by successful thyroidectomy under mechanical circulatory support (MCS) 
– one with a Heartmate III (Abbott Laboratories) and another supported with veno-
arterial extracorporeal membrane oxygenation (V-A ECMO). In refractory CS, the 
initiation of V-A ECMO as a bridge to recovery is critical. In thyrotoxicosis-induced 
CS that is refractory to medical therapy requiring MCS, thyroidectomy is feasible, 
and a growing body of evidence suggests that it is safe. 
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Background 
Left ventricular assist devices (LVADs) are being increasingly utilized as 
destination therapy, a bridge to candidacy, or a bridge to transplantation for 
patients with end stage heart failure (HF).1 While ventricular arrhythmias are 
common in patients supported by LVADs, they are also well-tolerated.2 
Amiodarone is an effective first line agent to treat ventricular arrhythmias post-
LVAD implantation. However, chronic treatment with amiodarone can lead to 
hyperthyroidism or hypothyroidism.3 Thyrotoxic cardiomyopathy (TCM) and 
thyrotoxicosis-induced cardiogenic shock (CS) are uncommon but critical 
complications of hyperthyroidism. Thyrotoxicosis-induced CS is a life-threatening 
event with a very high mortality.4,5 Therefore, patients in CS may benefit from 
veno-arterial extracorporeal membrane oxygenation (V-A ECMO) support. 
Although thyroidectomy is well-established in cases of refractory thyrotoxicosis, 
the safety and efficacy of thyroidectomy in patients with mechanical circulatory 
support (MCS) is uncertain. We describe two cases of thyrotoxicosis-induced CS. 
We briefly discuss the pathophysiology of thyrotoxicosis-induced CS, unsuccessful 
medical therapy, and successful thyroidectomy under MCS leading to the 




A 41-year-old male with a history of morbid obesity, obstructive sleep apnea, 
recurrent pulmonary embolism (PE), and end-stage HF with reduced ejection 
fraction (EF) due to nonischemic dilated cardiomyopathy presented to our hospital. 
The patient’s history included placement of a biventricular implantable 
cardioverter-defibrillator followed by a diagnosis of paroxysmal AF two years later. 
Amiodarone was prescribed to treat the AF. Eleven months later the patient was 
hospitalized for a PE and was receiving apixaban. During this hospitalization, the 
patient was diagnosed with hypothyroidism and started on low dose levothyroxine 
at discharge. His thyroid stimulating hormone (TSH) levels were continuously 
checked (Table 1). One month after the PE hospitalization, the patient received a 
HeartMate III LVAD (Abbott Laboratories) as a bridge to transplantation. The 
patient’s anticoagulation and antiplatelet regimen were aspirin (81 mg daily) and 
warfarin with an international normalized ratio (INR) goal between 2 and 3. Eight 
months after LVAD implantation, the patient’s post-operative course was 
complicated by a chronic Enterobacter driveline infection; doxycycline was 
prescribed. 
Two years after his LVAD implantation (37 months after the initiation of 
amiodarone), he presented to the hospital in severe respiratory distress. Over the 
previous 2 days, the patient suffered nausea, vomiting, diarrhea, and intermittent 
fevers. He was found to be in AF with rapid ventricular response (RVR) and was 
emergently intubated. The patient was in CS, and his initial vitals and laboratory 
results are presented in Table 2. Lactate dehydrogenase (LDH) was elevated  
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Table 1. Thyroid function tests for Case 1. The patient began receiving 
amiodarone for atrial fibrillation. He was diagnosed with hypothyroidism 11 months 
later and his levels were tracked from that point. *indicates the time of the 
hospitalization for thyroidectomy. 
Months after the 
initiation of 
amiodarone 






7.5 3.4 2.9 2.0 <0.01 3.1 
Free thyroxine 4 
(ng/dL) 1.0 N/A N/A N/A 5.4 1.2 
 
Table 2. Vital signs and laboratory results for Case 1. Upon presentation to our 
hospital, the patient was in cardiogenic shock and atrial fibrillation with rapid 
ventricular response. HR – heart rate; MAP – mean arterial pressure; LDH – 
lactate dehydrogenase; INR – international normalized ratio; AST/ALT – aspartate 
transaminase/alanine transaminase; Hgb-hemoglobin 



















8.4 134/ 68 
< 6 
mg/dl 2 mg/dl 
 
 
to 1508 from a baseline of 500 units/L. The haptoglobin was less than 6 mg/dl, 
which is well below the normal range of 30-200 mg/dl.  
The LVAD pump speed was increased from 6000 rpm to 6800 rpm to augment 
cardiac output with shock. Given the presence of elevated markers of hemolysis 
and CS, there was an initial concern for possible pump thrombosis or LVAD 
outflow tract obstruction. However, LVAD pump parameters were unchanged upon 
review (speed: 6800 rpm, flow: 2.7 L/min, power: 5.4 W, pulse index: 2.4). A 
computed tomography angiography of the chest showed mild peripheral 
circumferential low attenuation of the outflow graft, which was likely to be mild 
laminar thrombosis. Thus, no thrombolytics were used. Both the LDH and INR 
normalized without any intervention. Despite LVAD support, left ventricular (LV) 
systolic function remained severely depressed with an EF of 10%, and AF was 
refractory. Despite multiple cardioversions, amiodarone, and digoxin loading, the 
patient eventually required atrioventricular pacing due to arrhythmia-related 
hypotension. He required pressor support, multiple reintubations, and suffered 
recurrent fevers even though the infectious work up was negative.  
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A chest x-ray showed a pulmonary vascular congestion in keeping with volume 
overload, and his driveline culture was positive for known Enterobacter. He was 
started on empiric antibiotics. TSH was undetectable and reflex thyroxine (T4) was 
elevated (Table 1). At that time, thyrotoxicosis was felt to be causative of his 
refractory fever, diarrhea, AF, and CS. Endocrinology was consulted. Amiodarone 
was stopped while methimazole, steroids, and propranolol were started for thyroid 
storm due to suspected amiodarone-induced thyroiditis (AIT). However, surgery 
was a more definitive treatment for this patient due to his poor response to medical 
therapy. A total thyroidectomy was successful without any post-operative 
complications. Thyroid tissue pathology showed disrupted follicles with 
desquamated vacuolated epithelial cells, intra- and perifollicular aggregates of 
foamy macrophages, and follicles with flattened or apoptotic follicular cells 
consistent with AIT type 2. Post-thyroidectomy, his EF improved to 25%, and his 
sinus rhythm was successfully restored. The patient was discharged 5 days later in 
his usual state of health.   
 
Case Two 
A 51-year-old female with hyperthyroidism presented to the emergency 
department in AF with RVR (heart rate was 160 – 190 beats/min). She had a 
history of worsening dyspnea (one month), diarrhea (one week), and fevers (one 
week). She was not taking any medications for the hyperthyroidism.  
TSH was undetectable and free T4 was elevated (Table 3). Both diltiazem and 
esmolol were given, but neither successfully controlled the heart rate.  
 
Table 3. Thyroid function tests for Case 2. The patient’s thyroid function was 
monitored over the course of her hospitalization. A subtotal thyroidectomy was 
done on Day 9. 
Hospitalization Day 0 
(Admission) Day 6 Day 41 Day 59 
 
Thyroid stimulating hormone (mcU/mL) < 0.010 0.059 < 0.010 < 0.010 
 
Total thyroxine 4 (mCg/dL) 28.9 17.4  9.6 
 
Free thyroxine 4 (ng/dL) 5.2 2.1 0.7 1.1 
 
Total thyroxine 3 (ng/dL) 227 194   
 
Free thyroxine 3 (pg/mL 17.4  <10.0 1.5 
 
The patient was transferred to our tertiary center. Because she was in CS and 
suffering a thyroid storm, she was sedated, intubated, and initially treated with 
methimazole, propranolol, hydrocortisone, cholestyramine, and Lugol’s solution. 
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Both pressors and inotropic support were used to treat her hypotension. Due to 
her hemodynamic instability and sustained AF, a transesophageal echocardiogram 
was performed and showed de novo severely depressed LV function with an EF of 
10% and no left atrial appendage thrombus. She underwent multiple 
cardioversions. An amiodarone infusion was used first, and she was eventually 
transitioned to sotalol. The patient’s condition progressively deteriorated despite 
aggressive hemodynamic support with high doses of inotropic and vasopressor 
agents. Despite these interventions, episodes of AF continued unabated.  
She ultimately required plasmapheresis for her thyroid storm as her liver function 
values began to increase while on methimazole, likely secondary to CS. V-A 
ECMO was then initiated for worsening CS, lactic acidosis, increasing pressor 
requirements, and multisystem organ failure. She also needed continuous veno-
venous hemofiltration for hyperammonemia and anuria. Surgery was consulted for 
further management as she did not tolerate methimazole, and plasmapheresis was 
not a viable long-term solution.  
The risk of morbidity and mortality were deemed to be very high regardless of 
whether a thyroidectomy was done. After discussion with the patient’s family, an 
urgent total thyroidectomy with parathyroid auto transplant and tracheostomy was 
performed while the patient was on V-A ECMO support. The surgery was 
completed without complications, and she was decannulated from ECMO support 
on the same day as the thyroidectomy. In total, she received 155 hours (6.5 days) 
of ECMO support. 
Biopsy results revealed nodular hyperplasia and lymphocytic thyroiditis. An 
echocardiogram showed normal LV systolic function. Her heart rate normalized, 
and the rhythm changed from an AF to sinus rhythm. She remained sedated on 
propranolol. Her post-operative course was complicated by bleeding from her 
tracheal site, aspiration pneumonia, and Escherichia coli bacteremia which were 
all successfully treated. She was discharged 21 days after the thyroidectomy.  
 
Discussion 
In 2017, more than 3,000 patients were treated with LVADs.1 In 2019 alone, 3,597 
heart transplants were performed, and 4,086 new candidates were listed for heart 
transplantation.6 Ventricular arrhythmias occur in 20–50% of patients supported 
with LVADs.2 Chronic amiodarone therapy, while quite efficacious, is associated 
with thyroid dysfunction, which can occur in 5–10% of patients.3 
 
Hyperthyroidism leads to an increased serum concentration of triiodothyronine 
(T3), which up-regulates several cardiac-specific genes that enhance contractility, 
improve cardiac relaxation, lower the systemic vascular resistance, increase blood 
volume, and elevate the baseline heart rate.7 
Sustained tachycardia secondary to hyperthyroidism can impair LV contractility, 
increase atrial filling pressures, and lead to high-output HF. An untreated high-
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output state may eventually lead to ventricular dilatation and persistent tachycardia 
resulting in CS.8 
Cardiomyopathy is a rare complication of thyrotoxicosis and although about 6% of 
patients develop HF, less than 1% of the patients progress to dilated 
cardiomyopathy with systolic LV dysfunction and CS.4 Thyrotoxicosis-induced CS 
has a mortality as high as 30%.5 ECMO support may be required for hemodynamic 
support. 
There is also a high incidence of AF in thyrotoxicosis. In a population-based study 
of 40,628 patients diagnosed with hyperthyroidism, 8.3% were diagnosed as 
having AF or flutter within ±30 days from the date of the diagnosis.9 
Endothelial dysfunction, alterations in coagulation, and fibrinolytic pathways 
favoring a hypercoagulable state are known to occur in hyperthyroid states.10 
Elevated plasma-free thyroxine (T4) levels have also been associated with an 
increased risk of venous thrombosis independent of TSH levels.11 Despite 
anecdotal reports that suggest that there is an increased risk of pump thrombosis 
in LVAD patients who develop hyperthyroidism12 and elevated LDH, we did not 
encounter any issues with V-A ECMO cannula or LVAD thrombosis in our patients. 
Our suspicion of LVAD thrombosis was low because of the very low incidence 
encountered in the Heartmate III LVAD.13 
Early recognition of thyrotoxicosis as the culprit of the CS syndrome with typical 
symptoms of diarrhea, fevers, and recalcitrant AF was key to initiating aggressive 
medical treatment. Temporary MCS in the form of V-A ECMO was initiated in a 
timely manner when the patient continued to decline despite maximal medical 
support.  
Hyperthyroidism in both cases was difficult to treat despite an aggressive use of 
conventional medical therapy. First-line treatment with methimazole and steroids 
was unsuccessful, and propylthiouracil, plasmapheresis, and cholestyramine had 
to be added. It is important to note some cautions in medical treatment of patients 
with thyrotoxic CS and recurrent AF. Use of beta-blockers can worsen the CS, and 
amiodarone has a myocardial depressant effect and known hepatotoxicity that 
could worsen ischemic hepatic failure.  
Both patients’ hyperthyroidism continued despite medical management and 
underwent successful thyroidectomies. The surgeries resulted in the restoration of 
sinus rhythm. Case 1 required no escalation of MCS, and Case 2 was able to be 
weaned off of ECMO support. 
Of interest, the supratherapeutic INR of 8.4 in Case 1 could be explained by the 
fact that thyrotoxicosis increases plasma clearance of the vitamin K-dependent 
clotting factors. Thus, the dose of warfarin required to prolong the prothrombin 
time is smaller than usual.14 
What is unusual in case 2 is the rapid and complete normalization (< 24h) of 
myocardial function, which allowed for V-A ECMO weaning on the same day as 
the thyroidectomy after less than 6 days of support. One explanation is that, 
although rare, acute cardiomyopathy in hyperthyroidism occurs due to direct, toxic 
effects of thyroxine on the myocardium similar to catecholamine-induced 
cardiomyopathy. This has been previously described in pheochromocytoma and 
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major emotional stress.15,16 It has also been referred to as myocardial stunning in 
hyperthyroidism.17 The exact mechanism that facilitates the interaction between 
sympathoadrenal activity and thyroid hormones in the heart has yet to be fully 
elucidated. 
The potential for complete normalization of myocardial function is a key factor that 
should prompt initiation of V-A ECMO treatment as a bridge to recovery in similar 
cases of thyrotoxicosis-induced CS. 
Finally, successful thyroidectomy was curative, well-tolerated, and safe despite 
use of MCS in both cases. 
A limitation to our case series is the lack of invasive hemodynamic data, but this 
limitation is minimal since the etiology of shock was known. The CS rapidly 
worsened (within 24-48 hours) and was appropriately treated. This report also 
lacks long-term follow up data. 
Surveillance monitoring for patients with durable MCS on amiodarone should 
include checking free T4 and TSH levels at frequent intervals and monitoring for 
atrial arrhythmias. Discontinuation of amiodarone, maximizing beta blockade (if 
tolerated), or substitution with alternative antiarrhythmic agents should be 
considered when there is laboratory evidence of rising free T4 levels even if the 
TSH remains normal. 
 
Conclusion 
Thyrotoxicosis in patients with advanced HF can present as new onset 
decompensated HF leading to CS and/or de novo CS with recalcitrant atrial 
arrhythmias. Early recognition and appropriate treatment of a thyroid storm is 
critical to improve outcomes. As demonstrated, ECMO support should be 
considered in thyrotoxicosis-induced CS until thyroid hormone normalization is 
achieved. Finally, thyroidectomy is a safe and viable option to control 
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